You are here
Public submissions on scheduling matters referred to the ACMS #28, ACCS #26 and Joint ACMS-ACCS #23 meetings held in November 2019
Scheduling of chemicals and poisons
Published
Public submissions made in response to:
- the delegates' proposed amendments to the Poisons Standard published on 29 August 2019 and 19 September 2019 and received before the first closing date under regulation 42ZCZK of the Therapeutic Goods Regulations 1990 (the Regulations); and
- the delegates' interim decisions and invitation to comment published on 6 February 2020 and received before the second closing date under regulation 42ZCKP of the Regulations.
Public submissions on proposed amendments to be referred to an expert advisory committee
Public submissions on proposed amendments referred to the ACMS #28
*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open it from there.
Sumatriptan
- Industry stakeholder - The submitter did not give permission to publish their name or submission.
- Consultation submission: Australian Medical Association (pdf,167kb)
- Consultation submission: NSW Poisons Information Centre (pdf,240kb)
- Consultation submission: Pharmaceutical Society of Australia (pdf,1.86Mb)*
- Consultation submission: Pharmacy Guild of Australia (pdf,870kb)*
Zolmitriptan
Mometasone
- Industry stakeholder - The submitter did not give permission to publish their name or submission.
- Consultation submission: Australasian College of Dermatologists (pdf,1.2Mb)*
- Consultation submission: Australian Medical Association (pdf,167kb)
- Consultation submission: Consumer Healthcare Products (pdf,78kb)
- Consultation submission: Pharmaceutical Society of Australia (pdf,1.86Mb)*
- Consultation submission: Pharmacy Guild of Australia (pdf,870kb)*
Calcifediol
- Consultation submission: Australian Commission on Safety and Quality in Health Care (pdf,316kb)
- Consultation submission: NSW Poisons Information Centre (pdf,265kb)
- Consultation submission: Pharmaceutical Society of Australia (pdf,807kb)*
- Consultation submission: Pharmacy Guild of Australia (pdf,700kb)*
Paracetamol (liquid formulations)
- Consultation submission: Australian Commission on Safety and Quality in Health Care (pdf,316kb)
- Consultation submission: Consumer Healthcare Products (pdf,143kb)
- Consultation submission: GlaxoSmithKline Consumer Healthcare Australia Pty Ltd (pdf,882kb)
- Consultation submission: NSW Poisons Information Centre (pdf,265kb)
- Consultation submission: Pfizer Australia (pdf,126kb)
- Consultation submission: Pharmaceutical Society of Australia (pdf,807kb)*
- Consultation submission: Pharmacy Guild of Australia (pdf,700kb)*
- Consultation submission: Ronald Batagol (pdf,573kb)*
Paracetamol + ibuprofen
- Industry stakeholder - The submitter did not give permission to publish their name or submission.
- Consultation submission: Australian Commission on Safety and Quality in Health Care (pdf,316kb)
- Consultation submission: NSW Poisons Information Centre (pdf,265kb)
- Consultation submission: Pharmaceutical Society of Australia (pdf,807kb)*
- Consultation submission: Pharmacy Guild of Australia (pdf,700kb)*
Hyoscine butylbromide
Lidocaine
- Consultation submission: Australian Commission on Safety and Quality in Health Care (pdf,316kb)
- Consultation submission: NSW Poisons Information Centre (pdf,265kb)
- Consultation submission: Pharmaceutical Society of Australia (pdf,807kb)*
- Consultation submission: Pharmacy Guild of Australia (pdf,700kb)*
Public submissions on proposed amendments referred to the Joint ACMS-ACCS #23
Caffeine
Public submissions on proposed amendments referred to the ACCS #26
Carbon monoxide
- Australia New Zealand Industrial Gas Association - The submitter did not give permission to publish their submission.
- Consultation submission: Chemistry Australia (pdf,291kb)
- Consultation submission: NSW Poisons Information Centre (pdf,147kb)
Momfluorothrin
No submissions received
Tetraniliprole
No submissions received
Methiozolin
No submissions received
Lambda-cyhalothrin
No submissions received
Public submissions on interim decisions
Public submissions on proposed amendments referred to the ACMS #28
Sumatriptan
- Industry stakeholder - The submitter did not give permission to publish their name or submission.
- Consultation submission: Pharmacy Guild of Australia (pdf,144kb)
Zolmitriptan
- Industry stakeholder - The submitter did not give permission to publish their name or submission.
- Consultation submission: Pharmacy Guild of Australia (pdf,144kb)
Calcifediol monohydrate
Paracetamol (liquid formulations)
- Industry stakeholder - The submitter did not give permission to publish their name or submission.
- Consultation submission: Consumer Healthcare Products Australia (pdf,68kb)
Paracetamol + ibuprofen
No submissions received
Hyoscine butylbromide
No submissions received
Lidocaine
No submissions received
Public submissions on proposed amendments referred to the Joint ACMS-ACCS #23
Caffeine
N-methyl-2-pyrrolidone (NMP)
No submissions received
Public submissions on proposed amendments referred to the ACCS #26
Carbon monoxide
Momfluorothrin
No submissions received
Tetraniliprole
No submissions received
Methiozolin
No submissions received
Lambda-cyhalothrin
No submissions received
Outcome of
- ACMS #28, November 2019
- ACCS #26, November 2019
- Joint ACMS-ACCS meeting #23, November 2019
- Consultation: Proposed amendments to the Poisons Standard - ACMS and ACCS, November 2019
- Consultation: Proposed amendments to the Poisons Standard - ACMS and Joint ACCS/ACMS meetings, November 2019
- Advisory Committee on Medicines Scheduling (ACMS)
- Advisory Committee on Chemicals Scheduling (ACCS)